Market Access Biotech funding has returned. The bar has moved with it. For biotech sponsors, the question worth asking is not whether the rebound is real, but what it is actually rewarding.
Sales & Marketing Media Partner Why BIO-Europe 2026 matters: The evolution of strategic biop... 2026 marks a significant evolution for BIO-Europe.
Market Access JPM 2026: What it revealed about biotech’s new reality JPM 2026 signalled genuine recovery – but not the kind the industry has historically celebrated.
R&D Strategies for creating an ecosystem to support early-stage ... Learn how to foster growth for early-stage biotech companies through innovative ecosystem strategies and valuable CDMO collaborations
Market Access How can biotech survive its funding winter? Some may argue that VCs and public markets have turned against biotech, but the reality is they have become much more sceptical.
Market Access From roasts to billions: Navigating the biopharma investment... At BIO-Europe, the session “From Roasts to Billions: Biopharma Investment Landscape” brought together leading voices from investment banking & VC.
News ESC26: Isomab safety evidence on blood vessel growth for CAD Isomab has presented landmark safety data at ESC, clearing the path for next-generation therapies to promote blood vessel growth in CAD.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
